KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Depreciation & Amortization (CF) (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Depreciation & Amortization (CF) data on record, last reported at $9.4 million in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 0.91% year-over-year to $9.4 million; the TTM value through Dec 2025 reached $41.6 million, up 27.12%, while the annual FY2025 figure was $41.6 million, 27.12% up from the prior year.
  • Depreciation & Amortization (CF) reached $9.4 million in Q4 2025 per JAZZ's latest filing, down from $9.9 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $11.9 million in Q2 2025 and bottomed at $4.8 million in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $8.1 million, with a median of $7.7 million recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): soared 61.6% in 2021, then decreased 2.99% in 2023.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $7.3 million in 2021, then rose by 0.23% to $7.3 million in 2022, then increased by 4.14% to $7.6 million in 2023, then rose by 24.4% to $9.5 million in 2024, then fell by 0.91% to $9.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $9.4 million in Q4 2025, $9.9 million in Q3 2025, and $11.9 million in Q2 2025.